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The Winter meeting of the Nutrition Society was held at the Royal College of Physicians, London on 6–7 December 2011
70th Anniversary Conference on ‘Body weight regulation – food, gut
and brain signalling’
Symposium I: Food–gut interactions
The receptive function of hypothalamic and brainstem centres to
hormonal and nutrient signals affecting energy balance
Thomas Riediger
Institute of Veterinary Physiology and Centre of Integrative Human Physiology, University of Zurich,
8057 Zurich, Switzerland
The hypothalamic arcuate nucleus (ARC) and the area postrema (AP) represent targets for
hormonal and metabolic signals involved in energy homoeostasis, e.g. glucose, amylin, insulin,
leptin, peptide YY (PYY), glucagon-like peptide 1 (GLP-1) and ghrelin. Orexigenic neuro-
peptide Y expressing ARC neurons are activated by food deprivation and inhibited by feeding
in a nutrient-dependent manner. PYY and leptin also reverse or prevent fasting-induced acti-
vation of the ARC. Interestingly, hypothalamic responses to fasting are blunted in different
models of obesity (e.g. diet-induced obesity (DIO) or late-onset obesity). The AP also responds
to feeding-related signals. The pancreatic hormone amylin acts via the AP to control energy
intake. Amylin-sensitive AP neurons are also glucose-responsive. Furthermore, diet-derived
protein attenuates amylin responsiveness suggesting a modulation of AP sensitivity by mac-
ronutrient supply. This review gives an overview of the receptive function of the ARC and
the AP to hormonal and nutritional stimuli involved in the control of energy balance and the
possible implications in the context of obesity. Collectively, there is consistency between
the neurophysiological actions of these stimuli and their effects on energy homoeostasis under
experimental conditions. However, surprisingly little progress has been made in the develop-
ment of effective pharmacological approaches against obesity. A promising way to improve
effectiveness involves combination treatments (e.g. amylin/leptin agonists). Hormonal altera-
tions (e.g. GLP-1 and PYY) are also considered to mediate body weight loss observed in obese
patients receiving bariatric surgery. The effects of hormonal and nutritional signals and their
interactions might hold the potential to develop poly-mechanistic therapeutic strategies against
obesity.
Arcuate nucleus: Area postrema: Food intake: Obesity
Driven by the search for therapeutic treatment strategies
against obesity and associated metabolic disorders, con-
siderable knowledge has accumulated about the control
mechanisms involved in the maintenance of energy bal-
ance. The redundancy of control mechanisms, the capacity
of these systems to compensate for pharmacological
effects and the existence of obesity-related hormonal
insensitivities make it difficult to achieve sufficient
therapeutic efficiency for the reduction of body weight
over longer periods of time. Evidently, at least under non-
laboratory conditions, so-called non-homoeostatic factors
(hedonic properties and availability of food, food pre-
ferences, social factors, eating habits, etc.) and central
reward mechanisms override homoeostatic hormonal and
metabolic signals that are considered to reflect and to
control the body’s energy status.
Abbreviations: AMPK, adenosine monophosphate-activated protein kinase; AP, area postrema; APX, area postrema lesion; ARC, arcuate nucleus; CCK,
cholecystokinin; DIO, diet-induced obesity; FAS, fatty acid synthase; GLP-1, glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1 receptor;
mTOR, mammalian target of rapamycin; NED, non-energy diet; NPY, neuropeptide Y; NTS, nucleus of the solitary tract; OXM, oxyntomodulin; POMC,
pro-opiomelanocortin; PYY, peptide YY; STAT, signal transducer and activator of transcription.
Corresponding author: Thomas Riediger, fax + 41 44 635 8932, email triedig@vetphys.uzh.ch
Proceedings of the Nutrition Society (2012), 71, 463–477 doi:10.1017/S0029665112000778
g The Author 2012 First published online 29 August 2012
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0029665112000778
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:34:25, subject to the Cambridge Core terms of use, available at
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
In contrast to the currently available pharmacological
treatment options, bariatric surgery (e.g. Roux-en-Y gastric
bypass) is very effective in reducing body weight and
improving glucose homoeostasis in patients with type-2
diabetes mellitus(1,2). Apparently, bariatric surgery alters
gastrointestinal physiology in a way that changes nutrient-
induced gastrointestinal hormone responses, which pre-
sumably contribute to these therapeutic effects. Hence, the
signalling mechanisms of the gut–brain axis and the inter-
action between its nutritional and hormonal feedback sig-
nals are not only essential for our understanding of the
body’s energy homoeostasis but also for the ultimate desire
to develop pharmacological approaches against the obesity
epidemic. Some of the hormones (e.g. glucagon-like pep-
tide 1 (GLP-1) and peptide YY (PYY)) discussed in this
review with regard to their central actions are presumed as
mediators of weight loss after bariatric surgery. Although
the exact mechanisms behind bariatric weight loss surgery
and their potential to be targeted pharmacologically remain
to be identified, there are other promising therapeutic
approaches that are based on hormonal combination treat-
ments. Both pre-clinical studies in obese rodents and clin-
ical trials in human subjects have established a beneficial
effect of combined treatment with the anorexigenic pan-
creatic hormone amylin with the fat-derived hormone lep-
tin. Amylin treatment seems to reverse leptin insensitivity
in obese subjects, in which amylin and leptin exert a
synergistic action to reduce body weight(3,4).
Brain circuits involved in the control of energy balance
also function as fuel sensors responding to diet-derived
macronutrients. Nutrients not only alter neuronal activity
in feeding regulatory brain areas, they also modulate neu-
ronal responsiveness to hormonal stimuli. Two important
brain sites that are targeted by hormonal and nutrient sig-
nals involved in the control of energy balance are the
hypothalamic arcuate nucleus (ARC) and area postrema
(AP) of the brainstem. The current review focuses on the
receptive function of the ARC and the AP to feeding-
related signals and alterations of neuronal responsiveness
that are associated with obesity. It is beyond the scope of
this review to describe similar hormone and nutrient-
dependent signalling mechanisms in other brain areas that
also contribute to the overall control of energy homo-
eostasis.
The hypothalamic arcuate nucleus
The ARC is considered as one of the most important
hypothalamic target structures for blood-borne hormonal
and metabolic factors involved in the regulation of food
intake and energy homoeostasis. The best-characterised
hormone supposed to act via the ARC is the lipostatic and
anorectic hormone leptin, a 16 kDa protein that is secreted
from white adipose tissue. Genetic deficiency of leptin or
its receptor in rodents causes excessive food intake, body
weight gain and an obese phenotype(5,6). Leptin acts via
the ARC, which contains two functionally antagonistic
populations of neurons with respect to the control of
food intake. One population contains the orexigenic
neuropeptide Y (NPY) and agouti gene-related peptide(7).
The other distinct population synthesises the anorectic pro-
opiomelanocortin (POMC) gene product a-melanocyte
stimulating hormone(8). Leptin up-regulates POMC neu-
rons while it inhibits NPY/agouti gene-related peptide
neurons in the ARC(9,10). Similar to leptin, insulin fulfils
the criteria of an adiposity signal because circulating
insulin levels increase in relation to body adiposity. Fur-
thermore, insulin has access to the brain and it influences
food intake and body weight in a similar way as leptin via
the ARC(11).
Catalysed by the high importance of the ARC for body
weight control and the failure of leptin therapy as an
effective anti-obesity treatment because of leptin resis-
tance(12), the scientific interest in other factors acting via
the ARC and its downstream signalling pathways began to
increase. The well-established concept that the ARC is
targeted by the adiposity signals leptin and insulin has
been extended by numerous studies demonstrating ARC-
dependent actions of hormones, neuropeptides and meta-
bolites that change dynamically according to the status
of energy intake. Notably, leptin itself shows dynamic
short-term changes as a function of food intake(13,14).
Ghrelin
One of the hormones targeting the ARC is the orexigenic
gastrointestinal hormone ghrelin(15). Plasma levels of
ghrelin are modulated by the nutritional state. During
fasting and shortly before meals circulating ghrelin con-
centrations are elevated, while feeding or nutrient
intake reduce blood-ghrelin levels(16–18). Various electro-
physiological and immunohistological studies char-
acterised ghrelin’s effects on neuronal activity of ARC
neurons that have been suggested to represent target cells
for ghrelin in the brain(19–22). Ghrelin binds to the growth
hormone secretagogue receptor that is highly abundant in
the ARC(23). The growth hormone secretagogue receptor
is predominantly expressed in NPY neurons (94% co-
localisation), while it is found in only 8% of POMC neu-
rons(24). Ghrelin exerts opposite effects to leptin on the
activity of ARC neurons. Ghrelin or growth hormone
secretagogue receptor agonists excite leptin-inhibited NPY
neurons via a direct postsynaptic effect(19,25–27). In addition
to this action, ghrelin indirectly inhibits neurons of
the lateral ARC, where POMC neurons are located(20,28).
The excitatory effect of ghrelin on ARC neurons and the
NPYergic phenotype of these cells have been confirmed
in vivo by immunohistochemical studies using c-Fos as a
marker for neuronal activation(22,29).
Whether ghrelin can be considered a physiological sig-
nal in the control of energy homoeostasis has not yet been
confirmed based on the general criteria that have been
suggested to define a physiological relevance(30). Owing to
the weak consequences of ghrelin antagonism for feeding
behaviour or body weight phenotype and because of
the ineffectiveness of physiological ghrelin doses to pro-
duce feeding or body weight effects, the physiological
relevance of ghrelin has not yet been fully established(31).
Based on the leptin counter-regulatory action of ghrelin,
antagonism of ghrelin signalling has been proposed as a
therapeutic approach against obesity. However, the role of
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ghrelin in the pathogenesis of obesity is not clear. Ghrelin
levels in obese human subjects are lower than under nor-
mal weight conditions(32) limiting the usefulness and suc-
cess of ghrelin antagonism as an anti-obesity strategy(31).
Interestingly, weight loss in obese subjects seems to be
associated with an increase in ghrelin levels suggesting
that a blockade of ghrelin action might facilitate the body
weight reducing effect of other therapeutic interven-
tions(32). Notably, there is cumulating evidence for a role
of ghrelin in reward mechanisms that involve extra-hypo-
thalamic pathways originating in the ventral tegmental
area(33). The potential of pharmacological ghrelin-depen-
dent approaches with respect to this mechanism has not yet
been sufficiently explored in clinical studies.
Peptide YY/glucagon-like peptide 1
The two gut hormones PYY and GLP-1 act on ARC neu-
rons. They have received special attention in the context of
energy homoeostasis and as potential targets for the treat-
ment of overweight. Both hormones might contribute
to weight loss after gastric bypass surgery because
Roux-en-Y gastric bypass patients have increased GLP-1
and PYY levels and blockade of gastrointestinal hormone
release (including GLP-1 and PYY) by the somatostatin
analogue octreotide led to increased appetite(34–36). A spe-
cific role for PYY is suggested by the absence of weight
loss in PYY knockout mice subjected to gastrointestinal
bypass surgery(37).
PYY and PYY(3–36) are two biologically active pep-
tides arising from endocrine L-cells of the ileum and colon
in response to food intake(38). Although PYY binds to
several subtypes of Y receptors, PYY(3–36) exhibits rela-
tive specificity for the Y2 receptor(39). Both PYY isoforms
inhibit food intake after peripheral administration; but
PYY(3–36) appears to be more potent possibly due to
its specificity to the Y2 receptor that is decisive for the
anorexigenic response(40,41). However, the minimal doses
that were required to suppress food intake in these studies
were supraphysiological when compared with meal-
induced changes of total PYY blood levels. Therefore, the
question whether PYY(3–36) acts as a physiological
satiating signal is controversial. Direct site-specific injec-
tions of PYY(3–36) identified the ARC as possible central
target structure(42). With respect to the electrophysiological
effects of PYY(3–36) in the ARC, conflicting data exist in
the literature. In mice, PYY(3–36) has been demonstrated
to indirectly (presynaptically) excite phenotypically iden-
tified POMC neurons(42), while another electro-
physiological study demonstrated direct postsynaptic
inhibitions in POMC neurons of mice(43). Among others,
the reasons for these seemingly contradictory findings have
not yet been identified, but might be related to experi-
mental and technical differences concerning the slice pre-
paration and selection of cells(43). In rats, full-length PYY
exerts direct inhibitory effects on ghrelin-exited ARC
neurons (Fig. 1) suggesting that the NPYergic system is
also affected by PYY signalling(44). This is consistent
with the demonstration that PYY(3–36) inhibits NPY
release from ARC explants in addition to stimulating a
a-melanocyte stimulating hormone response(42).
Basal and postprandial PYY(3–36) levels are decreased
in obese human subjects and rodents(45). The absence of
PYY(3–36) resistance in obese subjects is in favour of
using PYY agonists as anti-obesity drugs. Chronic periph-
eral administration of PYY(3–36) decreases body weight in
different species including rhesus macaques(42,46,47). Whe-
ther PYY agonists can be therapeutically used in human
subjects to reduce body weight awaits further evaluation.
Interestingly, PYY seems to synergise with other hormones
or hormone agonists affecting the control of energy bal-
ance and glucose homoeostasis, including the GLP-1 ago-
nist exendin-4 and the pancreatic hormone amylin(48,49).
The neuronal correlates of these synergies are unknown.
Similar to PYY, GLP-1 is released in response to food
intake from gastrointestinal L-cells(50,51). GLP-1 plays an
important role in glucose homoeostasis (incretin) and gas-
trointestinal function(52). In addition to its peripheral
expression, GLP-1 is a neuropeptide expressed in a dis-
crete population of enteroceptive neurons located in the
brainstem(53). It binds to the GLP-1 receptor (GLP-1R) that
is also activated by the agonist exendin-4, a peptide that
has been isolated from the saliva of the lizard Heloderma
suspectum. The truncated form of exendin (9–39) (also
termed exendin-9) acts as a competitive antagonist at the
GLP-1R. The ARC, and other hypothalamic and brainstem
structures, including the paraventricular nucleus and the
AP, show high GLP-1R expression(54,55). Central and per-
ipheral injection GLP-1R agonists decrease food intake in
rodents(56–59). Furthermore, numerous studies have
demonstrated a GLP-1-mediated reduction in energy intake
in human subjects(60). Similar to ghrelin and PYY, it has
not yet been confirmed that endogenous GLP-1 physiolo-
gically controls food intake.
The neuronal mechanisms mediating the action of GLP-
1 on food intake have not yet been clearly identified, which
might be due to the fact that different pathways seem to
be activated depending on the experimental conditions,
particularly the route of administration and the potency
of the stimulus. While subdiaphragmatic deafferentation
Fig. 1. Continuous rate meter recording of a spontaneously active
neuron from the medial arcuate nucleus of the rat. Consecutive
superfusions of ghrelin and the anorectic hormone peptide YY
(PYY) at the indicated times caused opposite effects on neuronal
activity. While ghrelin induced a strong excitatory response, PYY
effectively decreased the discharge rate. Reproduced with permis-
sion (published in Riediger et al.(44)).
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blocked the anorexigenic effect of hepatic portal vein
GLP-1 infusion, subdiaphragmatic deafferentation did not
blunt the feeding suppressive effect of GLP-1 infused into
the vena cava(61). In contrast, the effect of the long-acting
GLP-1 agonist exendin-4 was not blocked in rats with
subdiaphragmatic deafferentation(62). There is some evi-
dence that the ARC represents a target site not only for
GLP-1 but also for the structurally related hormone oxy-
ntomodulin (OXM), which is co-secreted with GLP-1 and
exerts an anorexigenic effect via the GLP-1R after central
injection(63,64). GLP-1R activation by intra-arcuate injec-
tion of OXM decreased food intake and the OXM-medi-
ated suppression of intraperitoneal OXM administration
was blocked by injection of the GLP-1R antagonist exen-
din(9–39)(58). Another study did not observe a feeding
suppressive effect after intra-arcuate GLP-1 injection, but
hepatic glucose production was reduced under these con-
ditions(65). However, GLP-1 consistently reduced feeding
after site-specific injection into the paraventricular
nucleus(65,66).
The effects of GLP-1 and OXM on neuronal activity in
the ARC are similar. In rats, both hormones induced exci-
tatory responses in ghrelin-inhibited cells(67) (see example
in Fig. 2) suggesting a stimulation of POMC signalling,
which is consistent with the high expression of the GLP-
1R in POMC neurons(65). GLP-1 and OXM induced
heterogeneous excitatory and inhibitory effects in ghrelin-
excited ARC neurons, but the functional and neurochem-
ical phenotype of these cells have not yet been identified.
The absence of GLP-1R expression in NPY neurons seems
to exclude the NPY system as a primary target for GLP-1
in the ARC. Despite the existing in vivo and in vitro evi-
dence for a potential role of ARC-dependent GLP-1 sig-
nalling in energy and glucose homoeostasis further support
for a physiological role of endogenous GLP-1R ligands
acting via hypothalamic circuits needs to be established.
Although beneficial effects on body weight have been
reported for anti-diabetic GLP-1 agonists(68–70), moderate
effectiveness and undesired side effects limit the potential
of these drugs at least as a mono-therapy against obesity.
Feeding and nutrient-related effects on neuronal function
Numerous studies have confirmed the reciprocal regulation
of NPY and POMC gene expression in response to
alterations in energy intake(71). Fasting not only leads to
alterations in neuropeptide expression but also to altera-
tions in neuronal activity. Food deprivation for 24 h elicits
an activation of ARC neurons in mice as reflected by an
increase in c-Fos expression(72–74). Refeeding of 12 h food-
deprived mice completely reverses the fasting-induced
ARC activation (Fig. 3) indicating that feeding-related
signals exert a strong inhibitory effect on ARC neurons
that are activated under negative energy balance(44,75).
Hence, ARC neurons appear to respond to negative and
positive changes in energy intake. As demonstrated by
phenotyping studies, fasting-induced ARC activation spe-
cifically occurs in NPY neurons, but not in POMC neurons
under these conditions(75,76). While this observation sug-
gests increased hypothalamic NPY signalling as a result of
fasting, it does not exclude a parallel inhibition of POMC
neurons in the ARC. The induction of a fasting-induced
ARC activation has also been demonstrated in rats,
although considerably longer periods of food deprivation
(3 d) are typically required for an immunohistochemically
detectable response in this species, at least when c-Fos is
used as a marker. Interestingly, there seems to be a shift of
neuronal activation from the NPY system in the fasted
state to the melanocortin system following refeeding(77,78).
This response is consistent with the function of the NPY
system to promote energy intake under negative energy
balance and with the counter-regulatory function of the
POMC system to limit energy intake.
Feeding of palatable non-energy diet (NED; vanilla-fla-
voured cellulose) with or without selective nutrient sup-
plementation has proven to be a useful approach to explore
the role of diet-derived nutrients in feeding-related mod-
ulation of neuronal ARC activity. Mice receiving NED for
12 h instead of standard chow exhibit a strong c-Fos
expression in the ARC that is only slightly lower than in
12 h fasted animals(75). The same is true for fasted mice
that were refed with NED. Therefore, nutrient-independent
stimuli associated with feeding activity (e.g. gustatory,
oropharyngeal cues and gastric distension) appear to exert
a minor, but significant influence on the ARC because they
only weakly counteract the stimulation of ARC activation
triggered by short-term energy deprivation. When refeed-
ing with NED that was selectively supplemented with each
of the different macronutrients (carbohydrates, protein or
fat), a stronger reversal of fasting-induced ARC activation
was observed than that following refeeding with non-
supplemented NED(75). When the intake of each nutrient
was matched to specific nutrient intake of chow-fed ani-
mals, the carbohydrates were more effective than protein
and fat. However, increasing the protein content in the diet
or refeeding with pure fat (lard) resulted in a similar
reversal of fasting-induced c-Fos expression as observed
for refeeding with carbohydrate. Therefore, the relative
contribution of each macronutrient to the inhibition of
ARC activity in this experimental setting appeared to
depend on the amount of intake. Whether isoenergetic
intakes of the different macronutrients are equipotent to
reverse fasting-induced ARC activation has not yet been
investigated.
The mechanism underlying the fasting and feeding-
related effects on neuronal activity in the ARC are likely to
Fig. 2. Representative recording showing the excitatory effect of
glucagon-like peptide-1 (GLP-1) on a ghrelin-inhibited neuron of the
arcuate nucleus. Reproduced with permission (published in Riediger
et al.(67).
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indirect actions mediated by gastrointestinal hormones.
ARC neurons have been shown to respond to glucose in
excitatory and inhibitory ways(79). Phenotypically identi-
fied NPY neurons of mice and rats decrease their firing rate
with increasing glucose concentrations (glucose-inhibited
cells)(80,81). Conversely, POMC neurons have been
demonstrated to be glucose-excited because they decrease
their discharge rate when the extracellular glucose con-
centration is decreased(82,83). The intracellular mechanisms
transducing changes in the glucose concentration into
altered neuronal activity are well understood for glucose-
excited neurons, while the molecular correlates of inhibi-
tory glucose signalling are less clear. Glucose sensitivity in
glucose-excited neurons has obvious parallels to glucose
responsiveness of pancreatic b-cells, in which glucose
metabolism leads to increased ATP:ADP ratios. As a con-
sequence ATP induces a closure of the Kir6.2 pore-
forming subunit of the ATP-sensitive K + channel, leading
to a depolarisation of the cell. Genetic manipulations that
cause a loss of function of Kir6.2 subunit are associated
with a loss of glucose responsiveness in hypothalamic
neurons, including POMC neurons of the ARC(83,84).
Although the ATP-sensitive K + channel is required for the
glucose sensitivity of glucose-excited neurons, it is also
expressed in glucose-insensitive cells suggesting that other
molecular transducers are decisive for neuronal glucose
responsiveness. One of these transducers is the enzyme
glucokinase, the rate-limiting enzyme for glucose metabo-
lism in glucose sensitive neurons(85). Another enzyme that
seems to function as a master switch for intracellular
metabolic pathways including glucose metabolism is the
enzyme adenosine monophosphate-activated protein kinase
(AMPK). AMPK responds to changes in the ADP:ATP
ratio and induces counter-regulatory metabolic responses
through a variety of downstream targets(86). Hypothalamic
AMPK activity in the ARC and other hypothalamic struc-
tures is inhibited not only by leptin and insulin but also by
refeeding in fasted mice and by intraperitoneal and intra-
cerebroventricular glucose administration(87). Genetic
manipulation that results in constitutive hypothalamic
AMPK activity was associated with increased body weight,
while reduced AMPK activity resulted in reduced body
weight. These effects were partly attributed to changes in
food intake(87). Genetic disruption of AMPK in POMC and
NPY neurons was paralleled by a loss of glucose respon-
siveness of these cells in the ARC supporting of a role
of AMPK in glucose sensing(82). In line with the well-
established glucose sensitivity of ARC neurons, an
increase in circulating glucose after intraperitoneal glucose
administration reversed the fasting-induced ARC activa-
tion to a similar degree as refeeding(88). These studies do
not exclude indirect hormonal or vagal afferent signalling
mechanisms that might be engaged in parallel to a direct
action of glucose on ARC neurons.
Not only glucose but also hypothalamic fatty acid sig-
nalling contributes to the control of energy balance and
glucose homoeostasis because intracerebroventricular
infusion of oleic acid inhibits food intake and hepatic
glucose production(89,90). Besides other hypothalamic
structures, the ARC has been identified as a fatty acid
responsive area(91). Lipid sensitivity has been demonstrated
for POMC neurons that were inhibited by oleic acid(92). In
analogy to the importance of intracellular glucose meta-
bolism, intracellular lipid metabolism has been linked to
altered neuronal function and to changes in food intake and
body weight. Pharmacological blockade fatty acid synthase
(FAS) pathway by central or peripheral injection of the
FAS inhibitor C75 inhibited feeding and reduced body
weight in mice(93). Among other hypothalamic sites, FAS
is expressed in NPY neurons of the ARC(94). Peripherally
applied C75 prevented the fasting induced c-Fos expres-
sion in the medial ARC and in hypothalamic downstream
targets of the ARC supporting a role of lipid signalling in
fasting-induced ARC activation(95). Different intracellular
mechanisms have been proposed to mediate the effects of
FAS inhibition on energy homoeostasis. These mechan-
isms include an increase in the FAS substrate malonyl
CoA, which represents an intracellular metabolic signal
inhibiting food intake and body weight. This view is con-
sistent with the development of obesity and increased food
intake when malonyl CoA degradation in the mediobasal
hypothalamus is enhanced by overexpression of the
enzyme malonyl CoA decarboxylase(96). A regulatory
function for cellular lipid sensing has also been postulated
for the enzyme carnitine palmitoyltransferase-1 that con-
trols long-chain fatty acid transport into the mitochondria.
Pharmacological or genetic inhibition of hypothamalic
Fig. 3. Refeeding with chow completely reversed the fasting-induced c-Fos expression in the arcuate nucleus (ARC). Representative ARC
sections immunostained for c-Fos of 14-h fasted (A), chow-refed (B) and ad libitum chow-fed (C) mice. Bar charts show the quantitative
results of c-Fos expression (D). a,b Different letters indicate significant differences between groups (P<0.05). 3V: 3rd ventricle. Scale bar:
100mm. Reproduced with permission (published in Becskei et al.) (75).
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carnitine palmitoyltransferase-1 reduced food intake and
glucose production(97). Despite the cumulating evidence
for a role of hypothalamic lipid sensing further confirma-
tion is required for the physiological relevance of these
processes in the context of feeding-related or metabolically
induced changes in circulating mediators involved in lipid
signalling.
Similar to lipid signalling a role of hypothalamic amino
acid signalling in the control of food intake and body
weight has emerged. The serine-threonine kinase mamma-
lian target of rapamycin (mTOR) functions as nutrient
sensor implicated in cell growth and proliferation(98). Par-
ticularly branched amino acids such as leucine activate the
mTOR pathway. Components of the mTOR pathway have
been detected in 90 and 45% of ARC NPY and POMC
neurons, respectively(99). In analogy to the changes of
neuronal activity in the ARC as a result of fasting and
refeeding, activity of the mTOR pathway in the ARC is
down-regulated in the fasted state, while it increases in
response to refeeding. Both intracerebroventricular and
site-specific injection of leucine into the mediobasal
hypothalamus inhibited food intake(99,100). POMC neurons
of the ARC increase their electrical activity in response to
stimulation with leucine, which is consistent with in vivo
studies demonstrating a melanocortin receptor involvement
in the anorexigenic effect of mediobasal hypothalamic
leucin injection(100).
Fasting and the ingestion of each of the single macro-
nutrients lead to hormonal responses adjusting energy
homoeostasis and gastrointestinal function to the metabolic
and digestive requirements of the body. Some attempts
have been made to explore the involvement of hormones in
the feeding-related changes in ARC activity. Based on the
increase in ghrelin levels under fasting conditions, ghrelin
might contribute to the fasting-induced ARC activation in
mice. In rats, neutralisation of ghrelin by a site-specific
injection of anti-ghrelin Ig into the ARC attenuated food
intake in fasted animals during refeeding(101). An alter-
native approach to neutralise ghrelin is the use of an
L-RNA-based hormone antagonist, a so-called Spiegelmer,
that specifically binds and inactivates the bioactive form of
ghrelin(102,103). Owing to its long-lasting action a single
intravenous infusion of the anti-ghrelin Spiegelmer NOX-
B11-3 blocked the c-Fos response in the ARC of ad libitum
fed mice induced by exogenous ghrelin injected periph-
erally 12 h after administration of the antagonist(21). In the
same study, ghrelin antagonism did not significantly
attenuate the fasting-induced c-Fos response in the ARC
suggesting that endogenous ghrelin is not necessary for the
activation of the ARC under these experimental conditions.
Among the feeding-related hormones that are likely to
act via the ARC, ghrelin is the only hormone that increases
during fasting. Not only increases but also decreases in
hormone levels are likely to reflect alterations in energy
homoeostasis and metabolism. One experimental approach
to investigate this consists in the compensation of
decreased hormone levels by exogenous administration
of the respective hormone. Superimposed to the well-
described differences in leptin levels related to body adip-
osity, leptin plasma levels decrease considerably (5-fold) in
fasted v. ad libitum fed lean mice(75). Preventing the
fasting-induced decrease in leptin by repeated low-
dose leptin injections during the fasting period markedly
attenuated the c-Fos expression of in the ARC of food-
deprived mice (Fig. 4)(104). Despite the limitation of this
approach to precisely mimic physiological leptin levels by
exogenous leptin administration, this finding supports the
contribution of decreased leptin signalling to fasting-
induced ARC activation. Studies in leptin deficient ob/ob
mice seem to complement these findings because fasting-
induced ARC activation is exaggerated in ob/ob mice
compared with wild-type littermates(104). Together these
studies underscore that leptin signalling has an important
impact on the ARC in the context of feeding-related
modulation of ARC neurons.
Using the fasting/refeeding paradigm the possible
involvement of other hormones in feeding-related changes
of ARC activity has been studied. Similar to the ineffec-
tiveness of an acute leptin treatment to reverse fasting-
induced ARC activation, insulin did not attenuate c-Fos
expression in fasted animals regardless of whether a glu-
cose-lowering dose of insulin was used or a dose that did
not produce a reduction in blood glucose(75). Besides
insulin the anorexigenic hormones PYY, amylin and cho-
lecystokinin (CCK) were tested for their ability to reverse
fasting-induced c-Fos expression in the ARC. Only PPY,
but not amylin or CCK attenuated the stimulation of ARC
neurons in food-deprived mice(75,105). The lack of effec-
tiveness was probably not due to ineffective doses, because
in the same animals both amylin and CCK elicited c-Fos
expression in the AP and the nucleus of the solitary tract
(NTS), respectively. As amylin and CCK primarily act via
the brainstem (see later) and because the ARC is con-
sidered as a target site for PYY, these findings are con-
sistent with the presumed central signalling mechanisms
for these hormones. Despite the failure of CCK and amylin
to reverse fasting-induced ARC activation, at least CCK
partially prevented ghrelin-induced c-Fos expression in the
ARC in ad libitum fed mice(75) indicating some CCK-
dependent inhibitory input to the ARC. Collectively, these
findings suggest diverse roles for the investigated hor-
mones in feeding-related changes of neuronal function in
the ARC. However, the use of knockout models or specific
hormone antagonists is required to confirm the relevance of
endogenous hormone actions.
Altered neuronal arcuate nucleus responses in obese
rodent models
Obesity is associated with hormonal and metabolic per-
turbations, including hyperleptinaemia, hyperinsulinaemia,
leptin and insulin resistance, dyslipidaemia and hypergly-
caemia and others(12,106,107). In rodent models of diet-
induced obesity (DIO) neuronal to responsiveness of ARC
neurons to leptin is disrupted. DIO mice show a reduced
phosphorylation of the signal transducer and activator of
transcription 3 (STAT3), a marker for leptin receptor acti-
vation(108,109). Furthermore, the leptin-dependent release of
NPY and a-melanocyte stimulating hormone(110) is
decreased. As recently demonstrated, obesity also seems to
be associated with ghrelin resistance in the ARC because
peripheral or central ghrelin injection did not induce food
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intake and ARC activation in DIO mice(111). Moreover,
ghrelin failed to induce the release of NPY and agouti
gene-related peptide in hypothalamic explants from DIO
mice in this study. Not only hormonal resistance but also
impaired responsiveness of the ARC to metabolic stimuli
has been described(112).
It has been demonstrated in different obesity models that
obese mice show blunted neuronal responses of the ARC
to alterations in energy intake. Age-related obese (late-
onset obesity) and DIO mice show completely absent or a
strongly attenuated fasting-induced activation of NPY
neurons in the ARC depending on the duration of food
deprivation (12 h or 24 h, respectively). The blunted
responses in these animals were not due to age per se or
due to high-fat diet feeding because age-matched controls
and diet-resistant lean controls showed intense fasting-
induced c-Fos responses in the ARC(104,113). The absence
of fasting-induced ARC activation was associated with the
absence of refeeding hyperphagia that only occurred in
lean mice after fasting but not in late-onset obesity mice.
The blunted ARC activation in these hyperleptinaemic
obesity models contrasts with the exaggerated fasting
response in the ARC of obese leptin-deficient ob/ob
mice(113). Measurements of metabolic (blood glucose and
lipids) and hormonal parameters (insulin, ghrelin and lep-
tin) were conducted in fasted and ad libitum fed obese
mice and in respective lean controls(104,113). Among these
parameters, the only factor that consistently predicted the
altered neuronal responses across the different obesity
models was leptin because neuronal ARC activation is
enhanced under leptin deficiency, prevented by exogenous
leptin and blunted under hyperleptinaemia. However, the
idea that obesity-related hyperleptinaemia prevents the
response of the ARC to fasting is challenged by well-
described leptin resistance in hyperleptinaemic obesity.
Factors that limit central effectiveness of circulating leptin
involve reduced transport across the blood–brain barrier,
increased intracellular inhibition of leptin-signalling and
reduced leptin receptor expression. Each of these factors
are affected by feeding in a way that promotes leptin
responsiveness under fasting conditions. Fasting increases
the rate of leptin transport into the brain(114,115), reduces
intracellular leptin-antagonistic signalling(116,117) and
increases leptin receptor expression(118) and leptin binding
to the receptor(119). Hence, leptin responsiveness is
dynamic and linked to the feeding status. In line with this
assumption, fasting not only increases the leptin-induced
STAT3 phosphorylation in lean mice but also in late-onset
obesity mice that did not show a significant STAT3
response in the ad libitum fed state(104). Consequently, the
combination of increased leptin levels and increased
leptin responsiveness might prevent the activation of ARC
Fig. 4. Effect of exogenous leptin-induced hyperleptinaemia during fasting on arcuate
nucleus (ARC) activation in lean mice. Representative ARC sections immunostained for c-
Fos of young lean mice treated with saline or leptin every 3 h during a 14-h food-deprivation
period. Leptin treatment significantly increased the leptin plasma concentration and atte-
nuated the fasting-induced c-Fos expression in the ARC (**P<0.01 for both effects). 3 V: 3rd
ventricle. Scale bar: 100 mm. Reproduced with permission (published in Becskei et al.)(104).
Arcuate nucleus, area postrema and energy balance 469
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0029665112000778
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:34:25, subject to the Cambridge Core terms of use, available at
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
neurons under negative energy balance. Together, these
findings suggest that dynamic changes in leptin sensitivity
under hyperleptinaemia might interfere with the receptive
function of the ARC for stimuli reflecting short-term
excursions in energy intake.
The area postrema
The AP is a sensory circumventricular organ located in the
dorsal vagal complex of the brainstem. Owing to the lack
of a functional blood–brain barrier AP neurons can be
reached by humoral factors including peptide hormones
that do not passively cross the blood–brain barrier in other
areas of the brain. The AP is neuronally interconnected
with structures of the visceral enteroceptive neuroaxis
including the NTS and the lateral parabrachial nucleus
(120). Among other neuronal efferents the AP also projects
to the dorsal motor nucleus of the vagus that controls
visceral motor functions. The AP plays an important pro-
tective role as a so-called chemoreceptor trigger zone that
mediates aversive and emetic responses induced by nox-
ious or toxic stimuli. This function is for example reflected
by the absence of lithium chloride induced taste aversion
after ablation of the AP-lesioned (APX) in rats(121).
Observations from APX studies suggested an AP invol-
vement in the control of food intake and body weight.
APX rats are hypophagic and show lower body weight
compared with sham-lesions animals, although they
over-consume highly palatable food(122,123). Furthermore,
APX leads to loss of hypoglycaemic or glucoprivic
feeding responses induced by insulin, 2-deoxy-glucose
or 5-thio-glucose(122,124), suggesting a role of the AP in
central nervous glucose sensing.
Area postrema-mediated effects of amylin on food intake
The AP has been identified as a target structure for the
anorexigenic hormone amylin, which is widely accepted to
contribute to the physiological control of food intake.
Amylin is co-secreted with insulin from pancreatic b-cells
in response to meal-related stimuli(125). Amylin reduces
food intake at near physiological doses via a reduction of
meal size(126–128). Amylin antagonism not only blocks the
anorexigenic effect of exogenous amylin but also increases
food intake, supporting a physiological role of endogenous
amylin in energy intake(129). Numerous studies provided
evidence that the AP mediates amylin’s suppressive effect
on food intake. While vagal afferents are not required for
amylin’s anorexigenic action(130), APX blocks feeding
inhibitory action of amylin(131–133).
The effects of amylin on neuronal function in the AP
and the transmission of amylin signalling to other brain
structures involved in the control of energy homoeostasis
are well established. The amylin receptor consists of a
functional complex of the calcitonin receptor and so-called
receptor activity modifying proteins (receptor activity
modifying protein 1 and receptor activity modifying
protein 3)(134). The calcitonin receptor is densely ex-
pressed in the AP(135), where receptor activity modifying
protein 3 gene expression has also been described(136). In
electrophysiological studies, amylin exerted strong excita-
tory effects in 44% of the recorded spontaneously active
AP neurons(137). These effects were blocked by the amylin
receptor antagonist AC187 and appeared to be mediated
by the intracellular second messenger cyclic GMP. The
excitatory action of amylin on AP neurons is in line with
studies demonstrating an amylin-induced c-Fos expression
in the AP(137,138). Not only exogenous but also feeding-
related endogenous amylin activates AP neurons because
refeeding of fasted rats triggered a c-Fos response in the
AP that was attenuated by amylin antagonism(139). About
50% of neurons showing amylin-induced c-Fos are nora-
drenergic and specific neurotoxic lesion of these cells
blunted amylin’s feeding inhibitory action(140).
Interaction of amylin and nutrient signalling
Glucose. In support of the afore-mentioned evidence
for a role of the AP as central glucose sensor, electro-
physiological studies identified glucose-responsive neurons
in the AP(141). These studies were extended by the
demonstration that amylin-sensitive neurons in the AP are
specifically excited by glucose (Fig. 5), whereas amylin-
insensitive neurons are unresponsive to changes in the
ambient glucose concentration(142). Based on the impor-
tance of amylin-sensitive AP neurons for the physiological
control of feeding behaviour, these findings further support
a role of the AP in the metabolic control of food intake.
The AP is not the only glucose sensitive structure in the
brainstem, but it is located in a brainstem area where local
injection of 5-thio-glucose induced the strongest gluco-
privic feeding responses(143).
The glucose sensitivity of the AP has also been postu-
lated as a protective mechanism against excursions in
blood glucose values. Hypoglycaemia induces a counter-
regulatory increase in the rate of gastric emptying(144) that
compensates the decreased blood glucose via increased
gastrointestinal nutrient absorption. This mechanism inter-
feres with hormonal and pharmacological effects that delay
gastric emptying because glucose appears to be a permis-
sive factor. Amylin potently inhibits gastric emptying via
an AP-dependent action, which is overridden by hypogly-
caemia(145). Our group recently demonstrated a similar
permissive effect of glucose for amylin’s feeding suppres-
sive effect because amylin failed to significantly inhibit
feeding under hypoglycemic conditions (C Neuner-Boyle,
unpublished results). The inhibitory effect of the amylin
agonist pramlintide on gastric emptying is an important
therapeutic mechanism to lower postprandial glucose
levels in diabetic patients. As treatment-induced hypogly-
caemia is a severe risk in diabetic patients, the permissive
effect of glucose on gastric emptying is considered as a
fail-safe mechanism that overrides the anti-diabetic action
of amylin agonism under hypoglycaemic conditions
(see(146,147) for review).
Protein. Amylin’s satiating and effect and amylin-
induced AP activation are modulated by diet-derived
macronutrients, in particular by protein. An influence of
diet-derived nutrients on amylin signalling was inferred
from the observation that amylin-induced activation of the
AP is stronger in fasted v. ad libitum fed rats and also in
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rats that received nutrient-deficient NED(148). Selective
supplementation of NED with protein but not with glucose
or fat strongly attenuated the amylin-induced AP activation
suggesting that protein counteracts anorexigenic amylin
signalling. In light of the well-established satiating action
of protein this assumption appeared unexpected, but it was
confirmed by feeding studies in which amylin failed to
inhibit protein supplemented NED (Fig. 6)(148). The inhi-
bitory effect of diet-derived protein on amylin action has
been corroborated by immunohistological and feeding
studies using isoenergetic diets of different protein content.
Amylin more potently decreased intake of 1 and 8% pro-
tein chow than standard chow containing 18% protein.
Similarly, amylin-induced c-Fos expression was higher in
rats receiving less protein(149). These effects were not sec-
ondary to altered energy intake that was similar across the
experimental groups. While blood glucose levels were
also similar, blood amino acid levels decreased in rats fed
low-protein diet suggesting that circulating amino acids
might contribute the protein-dependent attenuation of
amylin-induced AP activation. Pre-treatment of rats with
an intraperitoneal administration of a mixed amino acid
solution also attenuated amylin’s c-Fos response in the AP,
which supports this hypothesis(149). However, the exact
neuronal mechanism underlying the protein-dependent
modulation of amylin signalling remains to be identified.
The relationship between reduced amylin-responsiveness
and protein intake might bear both physiological and
therapeutic implications. Amylin’s function in the control
of nutrient and energy intake might be adapted to the
nutrient composition of the diet. At least under undisturbed
energy homoeostasis protein is metabolically less impor-
tant than carbohydrate or fat, which might suggest that
amylin’s contribution to the overall control of energy
intake is stronger when the intake of protein relative to
glucose or fat is low. Another mutually not exclusive
implication might consist of an AP-sensitising effect pro-
duced by short-term reduction of food intake or food
availability in a protein-dependent manner, pre-adapting
AP responsiveness to a higher level in the pre-prandial
state before meal onset. In addition to the possible phy-
siological relevance, the effectiveness of pharmacological
Fig. 6. Effect of amylin (5 mg/kg s.c.) on food intake in rats kept on different test diets (NED, non-energy diet, vanilla-flavoured
cellulose) for 24 h prior to injection. Bars represent group means and SEM (n 12). *P<0.05 and ***P<0.001, significantly different
from respective control (saline) group (paired Student t test). Modified and reproduced with permission (published in Michel
et al.(148)).
–
Fig. 5. Co-sensitivity of an area postrema (AP) neuron to glucose and amylin. Decreasing the glucose
concentration in the superfusion solution from the standard concentration of 10mM to 2, 4 and 6mM
during the indicated time caused concentration-dependent decreases of the spontaneous discharge
rate. Superfusion of amylin elicited a strong excitatory effect. Reproduced with permission (published
in Riediger et al.(142)).
Arcuate nucleus, area postrema and energy balance 471
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0029665112000778
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:34:25, subject to the Cambridge Core terms of use, available at
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
approaches based on amylin agonism might be influenced
in a nutrient-dependent way.
Fat. There is not much experimental evidence for a
role of the AP in lipid sensing. Although lipoprivic feeding
induced by the fatty acid oxidation inhibitor mercaptoace-
tate is blunted in rats after AP/NTS lesion, this effect has
been attributed to the destruction of vagal terminal fields in
the NTS(150). Accordingly, lipoprivic feeding is also
blocked in vagotomised rats, confirming a mediation of
vagal afferent signals(150). Similarly, c-Fos expression
in the AP/NTS region after intraduodenal lipid infusion
is attenuated by capsaicin-induced destruction of vagal
afferents and by CCK receptor antagonism. The latter
finding indicates an indirect effect of intestinal lipid sen-
sing via CCK-mediated activation the vagal afferents sig-
nalling(151). It is reasonable to assume that amylin
signalling and vagally transmitted lipid/CCK dependent
signals converge at the level of the AP/NTS region. Fur-
thermore, the existence of a satiogenic synergy between
amylin and CCK(152) might imply that lipid-dependent
signals indirectly enhance amylin’s feeding suppressive
effect via a CCK-dependent action. Unlike the develop-
ment of hormonal resistance to leptin and insulin as a
consequence of prolonged high-fat diet feeding,
neither short-term nor long-term high-fat diet feeding leads
to amylin resistance at least when amylin’s inhibitory
action on food intake is used as an index of amylin
responsiveness(153).
Hormonal interactions involving area postrema and
brainstem mechanisms
The dorsal vagal complex is a site of convergence for
vagal and blood-borne signals controlling food intake.
Brainstem structures including amylin-sensitive sites are
reciprocally interconnected with hypothalamic and extra-
hypothalamic areas involved in energy homoeostasis(154).
For some hormones known to act via the brainstem
synergistic effects have been described, although the exis-
tence of a synergy is not always based on equal criteria in
the literature. Synergy is often inferred from the observa-
tion that the effect of two combined stimuli is higher than
the sum of the effects when each stimulus is applied alone.
Sophisticated statistical models (e.g. isobolographic ana-
lysis) have been used to detect and describe synergistic
actions. Several synergistic effects have been demonstrated
for amylin in combination with other hormones(155).
In addition to the synergy between amylin and CCK men-
tioned earlier, there is a synergistic effect of amylin and
leptin to reduce body weight in obese and lean subjects(3,4).
Several neuronal mechanisms have been associated with
the synergy between amylin and leptin. Amylin seems to
enhance neuronal leptin responsiveness as reflected by the
reversal of the blunted STAT3 response to leptin in the
ventromedial hypothalamus. Amylin also affects leptin
signalling in the brainstem because amylin knockout mice
tend to show reduced leptin-induced STAT3 phosphoryla-
tion in the NTS, and pre-treating leptin-resistant DIO rats
with amylin increased leptin-dependent STAT3 signalling
in the AP(3,4).
Anorexigenic synergy has also been reported for amylin
and PYY(3–36), whereas body weight reduction was
additive(49). The neuronal correlate of this anorexigenic
synergy has not yet been identified. While the AP was not
required for PYY(3–36)-induced suppression of feeding in
one study(156,157), another study suggested an involvement
of the AP in the PYY-dependent effects on gastric acid
secretion(158). Binding sites for PYY of the Y receptor
family are abundant in the AP(159–161). Interestingly, a dose
of full-length PYY that did not trigger a c-Fos response in
the AP alone, increased amylin-induced c-Fos expression
in the AP(105) suggesting a possible interaction between
amylin and PYY in the AP.
A recent study conducted in non-human primates
demonstrated anorexigenic synergy between the potent
amylin receptor agonist salmon calcitonin and the GLP-1R
agonist exendin-4(162). The mechanism underlying this
synergy also remains to be identified. There is evidence
that GLP-1 inhibits feeding via an AP-dependent effect
after hepatic portal vein infusion(163). However, the anor-
exigenic effect of exendin-4 is not blocked in APX
rats(164). Although amylin and GLP-1 activate AP neurons,
these hormones seem to have different target cells in the
AP. Similar to the aversive stimulus lithium chloride, GLP-
1 and exendin-4 almost exclusively activate AP neurons
that do not express the calcitonin receptor, which is con-
sidered as a marker for the primary target cells for amylin
in the AP(149). The functional implication of this dissocia-
tion has not yet been specifically investigated. GLP-
1R-mediated activation of the AP has been linked to the
induction of aversion(165). Therefore, it is particularly
important to exclude aversive mechanisms in approaches
based on GLP-1R activation.
Conclusions
Extensive evidence has accumulated demonstrating
that the ARC and the AP are responsive to hormonal and
nutrient-related signals involved in the homoeostatic feed-
back control of energy homoeostasis. Overall, the neuro-
physiological effects that have been described by a
multitude of different in vivo and in vitro approaches
are consistent with the effects of these signals on food
intake, body weight or metabolism. However, for many
of the discussed mechanisms, the physiological relevance
remains to be confirmed. Even when physiological
relevance is established (e.g. amylin) or postulated (ghre-
lin, PYY and GLP-1) the predictive value of these
physiological mechanisms for the effectiveness of mono-
therapeutic anti-obesity approaches targeting these mechan-
isms appears to be weak. Nevertheless, the impressive
effectiveness of bariatric surgery suggests the existence of
signalling mechanisms that potently reduce body weight and
improve metabolic disorders without being compensated by
the body. Obviously, the interaction between the different
feedback signals has been underestimated, which is reflected
by the promising improvements in the therapeutic outcome
of combination treatments. The concept of the homoeostatic
feedback control of energy homoeostasis needs to be
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integrated into the increasing knowledge about the non-
homoeostatic controls affecting energy balance.
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